4Markwardt F. The development of hirudin as anantithrombotie drug [ J ]. Thrombosis Research, 1994,74 ( 1 ) : 1 - 23.
5Mitsngu F, Kyongsu H. Thromlbolytic effect of nattokinase on chemically induced thrombosis model in rat[ J ]. Bio Pham Bull, 1995,18 (10) : 1387 - 1391.
6Dawson DL,Cuder BS, Meissner Mtt,et al. Cilostazol has benefi- ciM effects in treatment of intermittent claudication : results from muhicenter, randomized, prospective, double - blind trial [ J ] Circulation, 1998,98:678 - 686.
8Goto S,Tamura N,Eto K,et al. Functional significance of adeno- sine 5"- diphosphate receptor( P2Yt2 ) in plate let activation initia- ted by binding of yon Willebrand factor to platelet GP Ibct induced by conditions of high shear rate [ J ]. Circulation, 2002,105 : 9531 - 2536.
9Harker LA, Boissel JP, Pilgrim A J, et al. Comparative safety and tolerability of clopidogrel and aspirin : Results from CAPR 1E. CA- PR IE steering committee and investigators, copidogrel vs. aspi- rin in patients at risk of ischaemic events[J]. Drug Saf, 1999, 21:325 - 335.
10Bertrand ME, Rupprecht HI, Urban P, et al. Double - blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combi- nation with aspidn after coronmy stenting:The Clopidegrel Aspi- rin Stent International Cooperative Study (CLASSICS) [ J ] ~ Circulation ,2000,102 ( 6 ) :624 - 629.
10FitzGerald G A, Lupinetti M, Charman S A, Charman W N. Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2 [ J].Pharmacol Exp Ther, 1991,259 : 1043 - 9.
